Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders

NCT00684268 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: Silibinin
DRUG: Silibinin

Sponsor

Medical University of Vienna